Bill Wexler's Trading Cabana Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ggersh who wrote (5236)	4/3/2009 7:57:51 PM
From: RockyBalboa	Read Replies (1) of 6370

DNDN - fine! It even rose afterhours to mid-6 or so. But this is nothing I want to own longer than a couple of hours. DNDN has put some dirt on because they disclosed study results when they should not (in October 2008). It could very well end like GNTA if their lead drug hits a snafu. And their net cash is practically zero (they had 100MM but 90M in debt). A "final" presentation of DNDN is due late april (april 28?) past the current options expiration. By then the fate of the comapny should be sealed. reuters.com But - all is rumor: >>>>>>>>> NEW YORK, April 3 (Reuters) - Shares of Dendreon Corp (DNDN.O) jumped 38 percent on Friday as investors looked ahead to long-awaited data on the company's experimental Provenge vaccine to treat advanced prostate cancer. A spokeswoman for the U.S. biotechnology company, Katherine Stueland, said she knew of no clear reason for the stock gains. But she noted that the American Urological Association on Friday had reserved a time slot at one of its upcoming scientific meetings for Provenge researchers to present findings from a late-stage trial of the product. "We don't know whether we'll definitely be releasing the data there," said Stueland, who noted that the urological group had invited it to make a "late-breaker" presentation on April 28 at its meeting in Chicago. Late-breaker presentations at medical meetings usually involve high-profile studies, or ones of particular interest to healthcare professionals. However, selection of studies as a late breaker is no indication whether the data will be positive or negative. Stueland reaffirmed that Dendreon expects to release the Provenge data by the end of the month, even if the urological group's meeting is not the chosen forum. <<<<<<<<<<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next